Patent Ductus Arteriosus Clinical Trials

4 recruitingLast updated: May 4, 2026

Patent Ductus Arteriosus Trials at a Glance

10 actively recruiting trials for patent ductus arteriosus are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Québec, Toronto, and Dublin. Lead sponsors running patent ductus arteriosus studies include Hamilton Health Sciences Corporation, IWK Health Centre, and Ain Shams University.

Browse patent ductus arteriosus trials by phase

Treatments under study

About Patent Ductus Arteriosus Clinical Trials

Looking for clinical trials for Patent Ductus Arteriosus? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Patent Ductus Arteriosus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Patent Ductus Arteriosus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting

NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Circulation Pilot

SepsisStrokePulmonary Hypertension+4 more
St. Olavs Hospital180 enrolled1 locationNCT06646250
Recruiting
Phase 2

Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants

Patent Ductus Arteriosus After Premature Birth
Mount Sinai Hospital, Canada310 enrolled9 locationsNCT05340582
Recruiting
Not Applicable

PREEMIE: Study for Treatment of PDA in Premature Infants

Patent Ductus Arteriosus (PDA)
Merit Medical Systems, Inc.55 enrolled10 locationsNCT06587282
Recruiting

PDA for Kidneys Study

Congenital Heart DiseasePatent Ductus Arteriosus
University of Wisconsin, Madison45 enrolled1 locationNCT06658496
Recruiting

Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects

Patent Ductus Arteriosus
Occlutech International AB255 enrolled15 locationsNCT05264753
Recruiting

Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates

Neonatal PrematurityPatent Ductus Arteriosus in Preterm InfantsProstaglandins
Ain Shams University34 enrolled1 locationNCT07338370
Recruiting
Phase 2

Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT

PretermPatent Ductus Arteriosus
Hamilton Health Sciences Corporation26 enrolled1 locationNCT07143201
Recruiting
Phase 3

Selective Early Medical Treatment of Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot RCT

Patent Ductus Arteriosus After Premature Birth
IWK Health Centre100 enrolled9 locationsNCT05011149
Recruiting

Paracetamol and Patent Ductus Arteriosus closure: Pharmacokinetic-Pharmacodynamic study

Patent Ductus Arteriosus (PDA) in preterm neonatesParacetamol therapy for PDA closure.
Monash Health50 enrolled1 locationACTRN12623001197628
Recruiting
Phase 3

Treatment of Patent Ductus Arteriosus with Paracetamol

Patent ductus arteriosus in very low birth weight neonates
Sapienza University of Rome90 enrolled1 locationACTRN12613000289718